AIM
HEALTHCAREAIM ImmunoTech Inc
$0.48-0.04 (-6.96%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving AIM Today?
No stock-specific AI insight has been generated for AIM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.46$14.92
$0.48
Fundamentals
Market Cap$4M
P/E Ratio—
EPS$-8.62
Dividend Yield—
Dividend / Share—
ROE-31.4%
Profit Margin—
Debt / Equity—
Trading
Volume176K
Avg Volume (10D)—
Shares Outstanding8.1M
AIM News
20 articles- AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination PotentialYahoo Finance·May 7, 2026
- AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IPYahoo Finance·Apr 16, 2026
- AIM ImmunoTech Provides Routine Update on Annual FilingsGlobeNewswire Inc.·Apr 13, 2026
- AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell EventYahoo Finance·Apr 9, 2026
- AIMIA PROVIDES UPDATE ON ITS SHARE BUYBACKSYahoo Finance·Apr 1, 2026
- We Might See A Profit From Aimia Inc. (TSE:AIM) SoonYahoo Finance·Mar 26, 2026
- Aimia Q4 Earnings Call HighlightsMarketbeat·Mar 24, 2026
- Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer TrialYahoo Finance·Mar 24, 2026
- AIMIA REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTSYahoo Finance·Mar 24, 2026
- AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint InhibitorsYahoo Finance·Mar 18, 2026
- AIM ImmunoTech Announces Closing of its Rights OfferingYahoo Finance·Mar 7, 2026
- AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 MillionYahoo Finance·Mar 4, 2026
- AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic CancerYahoo Finance·Mar 2, 2026
- AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights OfferingYahoo Finance·Feb 27, 2026
- AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026Yahoo Finance·Feb 25, 2026
- AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic CancerYahoo Finance·Feb 23, 2026
- CORRECTION: AIM ImmunoTech Announces Commencement of Rights OfferingYahoo Finance·Feb 12, 2026
- AIM ImmunoTech Announces Commencement of Rights OfferingYahoo Finance·Feb 11, 2026
- JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026Yahoo Finance·Feb 9, 2026
- AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull FinancialYahoo Finance·Feb 6, 2026
All 20 articles loaded
Price Data
Open$0.51
Previous Close$0.52
Day High$0.51
Day Low$0.49
52 Week High$14.92
52 Week Low$0.46
52-Week Range
$0.46$14.92
$0.48
Fundamentals
Market Cap$4M
P/E Ratio—
EPS$-8.62
Dividend Yield—
Dividend / Share—
ROE-31.4%
Profit Margin—
Debt / Equity—
Trading
Volume176K
Avg Volume (10D)—
Shares Outstanding8.1M
About AIM ImmunoTech Inc
AIM ImmunoTech Inc., an immunpharmaceutical company, focuses on research and development of therapies to treat multiple types of cancers, viruses, and immunodeficiency disorders in the United States. The company is headquartered in Ocala, Florida.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security Type—
ExchangeAMEX
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—